What is Yubo International Biotech Limited's earnings per share (EPS)?

Yubo International Biotech Limited (YBGJ) reported diluted earnings per share of $-0.01 for fiscal year 2025. This represents a 50.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Yubo International Biotech Limited Financials

YBGJ

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE March

This page shows Yubo International Biotech Limited (YBGJ) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

3/9

Yubo International Biotech Limited passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.52x

For every $1 of reported earnings, Yubo International Biotech Limited generates $0.52 in operating cash flow (-$843K OCF vs -$1.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$12K

YoY+256.0%

5Y CAGR-60.9%

Yubo International Biotech Limited generated $12K in revenue in fiscal year 2025. This represents an increase of 256.0% from the prior year.

EBITDA

-$1.0M

YoY+36.2%

Yubo International Biotech Limited's EBITDA was -$1.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 36.2% from the prior year.

Net Income

-$1.6M

YoY+17.8%

Yubo International Biotech Limited reported -$1.6M in net income in fiscal year 2025. This represents an increase of 17.8% from the prior year.

EPS (Diluted)

$-0.01

YoY+50.0%

Yubo International Biotech Limited earned $-0.01 per diluted share (EPS) in fiscal year 2025. This represents an increase of 50.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$8K

YoY+14.9%

5Y CAGR-64.3%

10Y CAGR-3.9%

Yubo International Biotech Limited held $8K in cash against $70K in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

170M

5Y CAGR+7.6%

Yubo International Biotech Limited had 170M shares outstanding in fiscal year 2025.

Margins & Returns

Gross Margin

66.1%

YoY-10.2pp

5Y CAGR-25.5pp

Yubo International Biotech Limited's gross margin was 66.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 10.2 percentage points from the prior year.

Operating Margin

-9614.6%

YoY+41391.7pp

5Y CAGR-9562.1pp

Yubo International Biotech Limited's operating margin was -9614.6% in fiscal year 2025, reflecting core business profitability. This is up 41391.7 percentage points from the prior year.

Net Margin

-13186.3%

YoY+43925.8pp

5Y CAGR-13133.7pp

Yubo International Biotech Limited's net profit margin was -13186.3% in fiscal year 2025, showing the share of revenue converted to profit. This is up 43925.8 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

YBGJ Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$12K+256.0%	$3K-99.4%	$605K+479.8%	$104K-91.6%	$1.2M-8.1%	$1.4M
Cost of Revenue	$4K+409.5%	$822-99.6%	$185K+259.3%	$52K-87.8%	$424K+270.8%	$114K
Gross Profit	$8K+208.3%	$3K-99.4%	$419K+696.1%	$53K-93.6%	$821K-33.8%	$1.2M
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	$29K
Operating Income	-$1.2M+32.9%	-$1.8M-48.1%	-$1.2M+0.9%	-$1.2M+21.9%	-$1.5M-116.8%	-$712K
Interest Expense	N/A	$50+113.3%	-$377-264.6%	$229-46.4%	$427+14333.3%	-$3
Income Tax	N/A	$0	$0	$0	$0	$0
Net Income	-$1.6M+17.8%	-$2.0M-65.8%	-$1.2M+0.8%	-$1.2M+21.9%	-$1.5M-116.7%	-$712K
EPS (Diluted)	$-0.01+50.0%	$-0.02+80.0%	$-0.10	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$0	$0	$0	N/A	$0	$0-100.0%	$3K-80.8%	$18K
Cost of Revenue	$0	$0	$0	N/A	$0	$0-100.0%	$827-48.1%	$2K
Gross Profit	$0	$0	$0	N/A	$0	$0-100.0%	$3K-83.9%	$17K
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	-$310K-24.2%	-$250K+46.6%	-$467K	N/A	-$533K-13.2%	-$470K-14.9%	-$409K+20.9%	-$517K
Interest Expense	$18-21.7%	$23+221.1%	-$19	N/A	$49+188.2%	$17-79.8%	$84+112.1%	-$693
Income Tax	$0	$0	$0	N/A	$0	$0	$0	$0
Net Income	-$310K-34.7%	-$230K+47.1%	-$436K	N/A	-$621K-17.7%	-$528K-39.8%	-$377K+27.1%	-$517K
EPS (Diluted)	$0.00	$0.00	$0.00	N/A	$-0.01	$0.00	$0.00	N/A

YBGJ Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$847K-44.8%	$1.5M-7.9%	$1.7M-29.0%	$2.3M-48.8%	$4.6M+87.6%	$2.4M
Current Assets	$668K-2.2%	$683K-5.9%	$725K-3.3%	$750K-29.1%	$1.1M-44.6%	$1.9M
Cash & Equivalents	$8K+14.9%	$7K+10.3%	$6K-65.1%	$18K-33.8%	$28K-98.0%	$1.4M
Inventory	$24K-35.0%	$37K-82.8%	$215K-33.4%	$322K+96.1%	$164K+144.7%	$67K
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.8M-42.2%	$4.8M+37.6%	$3.5M+20.5%	$2.9M-38.2%	$4.7M+269.4%	$1.3M
Current Liabilities	$2.8M-40.9%	$4.7M+39.1%	$3.4M+34.6%	$2.5M-9.6%	$2.8M+118.4%	$1.3M
Long-Term Debt	$70K	N/A	N/A	N/A	N/A	N/A
Total Equity	-$2.0M+42.9%	-$3.4M-85.7%	-$1.8M-226.1%	-$565K-330.9%	-$131K-111.2%	$1.2M
Retained Earnings	-$7.7M-16.2%	-$6.7M-36.3%	-$4.9M-32.4%	-$3.7M-48.5%	-$2.5M-163.6%	-$943K

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$953K-9.4%	$1.1M-9.8%	$1.2M-24.0%	$1.5M-7.2%	$1.7M-4.3%	$1.7M+11.6%	$1.5M-7.1%	$1.7M
Current Assets	$650K-1.4%	$659K-3.8%	$685K+0.4%	$683K-5.7%	$724K-4.9%	$761K+3.6%	$735K+1.3%	$725K
Cash & Equivalents	$11K+4.9%	$10K+6.6%	$10K+39.3%	$7K-12.7%	$8K+4.3%	$8K-86.5%	$57K+796.7%	$6K
Inventory	$38K+0.6%	$38K+1.2%	$37K+0.7%	$37K+462.1%	$7K-92.4%	$87K-59.0%	$212K-1.3%	$215K
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.6M-49.2%	$5.0M+4.6%	$4.8M-0.4%	$4.8M+2.9%	$4.7M+13.2%	$4.1M+15.0%	$3.6M+2.8%	$3.5M
Current Liabilities	$2.6M-49.2%	$5.0M+5.1%	$4.8M+1.3%	$4.7M+5.2%	$4.5M+13.6%	$4.0M+12.3%	$3.5M+3.6%	$3.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$1.7M+58.4%	-$4.0M-9.0%	-$3.7M-7.2%	-$3.4M-9.4%	-$3.1M-24.0%	-$2.5M-22.1%	-$2.1M-12.1%	-$1.8M
Retained Earnings	-$7.5M-2.1%	-$7.3M-3.2%	-$7.1M-6.5%	-$6.7M-4.5%	-$6.4M-10.0%	-$5.8M-10.0%	-$5.3M-7.7%	-$4.9M

YBGJ Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$843K+37.0%	-$1.3M-81.0%	-$739K-23.0%	-$601K+41.1%	-$1.0M-1109.7%	$101K
Capital Expenditures	N/A	N/A	N/A	$0-100.0%	$565K+1227.0%	$43K
Free Cash Flow	N/A	N/A	N/A	-$601K+62.1%	-$1.6M-2808.0%	$59K
Investing Cash Flow	$118K0.0%	$118K	$0+100.0%	-$40K+93.0%	-$565K-479.4%	-$97K
Financing Cash Flow	$850K-39.6%	$1.4M+88.7%	$746K+11.4%	$669K+426.2%	$127K-90.8%	$1.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$359K-1069.1%	$37K+109.5%	-$392K+58.0%	-$933K-364.0%	$353K+182.6%	-$428K-29.4%	-$331K+40.8%	-$558K
Capital Expenditures	N/A	N/A	$6K	N/A	N/A	N/A	$19K	N/A
Free Cash Flow	N/A	N/A	-$398K	N/A	N/A	N/A	-$350K	N/A
Investing Cash Flow	$0-100.0%	$86K+1491.7%	-$6K	$0-100.0%	$36K-67.4%	$112K+473.2%	-$30K	$0
Financing Cash Flow	$0-100.0%	$196K-29.4%	$278K-75.0%	$1.1M+363.8%	-$421K-202.5%	$410K+33.1%	$308K-58.7%	$746K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

YBGJ Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	66.1%-10.2pp	76.3%+7.0pp	69.3%+18.8pp	50.5%-15.5pp	66.0%-25.6pp	91.6%
Operating Margin	-9614.6%+41391.7pp	-51006.3%-50808.7pp	-197.6%+958.1pp	-1155.7%-1031.7pp	-124.0%-71.4pp	-52.6%
Net Margin	-13186.3%+43925.8pp	-57112.2%-56914.5pp	-197.6%+957.9pp	-1155.5%-1031.5pp	-124.0%-71.4pp	-52.6%
Return on Equity	N/A	N/A	N/A	N/A	N/A	-61.0%
Return on Assets	-192.3%-63.2pp	-129.1%-57.4pp	-71.7%-20.4pp	-51.3%-17.7pp	-33.6%-4.5pp	-29.1%
Current Ratio	0.24+0.1	0.14-0.1	0.21-0.1	0.30-0.1	0.38-1.1	1.49
Debt-to-Equity	-0.04+1.4	-1.41+0.5	-1.90+3.2	-5.15+30.8	-35.96-37.1	1.09
FCF Margin	N/A	N/A	N/A	-576.3%-448.9pp	-127.4%-131.7pp	4.3%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	76.3%-14.9pp	91.2%
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	-11738.0%-8883.2pp	-2854.8%
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	-10817.0%-7961.8pp	-2855.2%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-32.5%-10.6pp	-21.9%+15.4pp	-37.4%	N/A	-37.5%-7.0pp	-30.5%-6.2pp	-24.3%+6.7pp	-31.0%
Current Ratio	0.25+0.1	0.13-0.0	0.140.0	0.14-0.0	0.16-0.0	0.19-0.0	0.210.0	0.21
Debt-to-Equity	-1.54-0.3	-1.26+0.1	-1.31+0.1	-1.41+0.1	-1.50+0.1	-1.64+0.1	-1.75+0.2	-1.90
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	-10020.8%	N/A

Note: Shareholder equity is negative (-$2.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.24), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Frequently Asked Questions

What is Yubo International Biotech Limited's annual revenue?

Yubo International Biotech Limited (YBGJ) reported $12K in total revenue for fiscal year 2025. This represents a 256.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Yubo International Biotech Limited's revenue growing?

Yubo International Biotech Limited (YBGJ) revenue grew by 256% year-over-year, from $3K to $12K in fiscal year 2025.

Is Yubo International Biotech Limited profitable?

No, Yubo International Biotech Limited (YBGJ) reported a net income of -$1.6M in fiscal year 2025, with a net profit margin of -13186.3%.

What is Yubo International Biotech Limited's EBITDA?

Yubo International Biotech Limited (YBGJ) had EBITDA of -$1.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Yubo International Biotech Limited have?

As of fiscal year 2025, Yubo International Biotech Limited (YBGJ) had $8K in cash and equivalents against $70K in long-term debt.

What is Yubo International Biotech Limited's gross margin?

Yubo International Biotech Limited (YBGJ) had a gross margin of 66.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Yubo International Biotech Limited's operating margin?

Yubo International Biotech Limited (YBGJ) had an operating margin of -9614.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Yubo International Biotech Limited's net profit margin?

Yubo International Biotech Limited (YBGJ) had a net profit margin of -13186.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Yubo International Biotech Limited's operating cash flow?

Yubo International Biotech Limited (YBGJ) generated -$843K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Yubo International Biotech Limited's total assets?

Yubo International Biotech Limited (YBGJ) had $847K in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does Yubo International Biotech Limited have outstanding?

Yubo International Biotech Limited (YBGJ) had 170M shares outstanding as of fiscal year 2025.

What is Yubo International Biotech Limited's current ratio?

Yubo International Biotech Limited (YBGJ) had a current ratio of 0.24 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Yubo International Biotech Limited's debt-to-equity ratio?

Yubo International Biotech Limited (YBGJ) had a debt-to-equity ratio of -0.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Yubo International Biotech Limited's return on assets (ROA)?

Yubo International Biotech Limited (YBGJ) had a return on assets of -192.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Yubo International Biotech Limited's cash runway?

Based on fiscal year 2025 data, Yubo International Biotech Limited (YBGJ) had $8K in cash against an annual operating cash burn of $843K. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Yubo International Biotech Limited's debt-to-equity ratio negative or unusual?

Yubo International Biotech Limited (YBGJ) has negative shareholder equity of -$2.0M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Yubo International Biotech Limited's Piotroski F-Score?

Yubo International Biotech Limited (YBGJ) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Yubo International Biotech Limited's earnings high quality?

Yubo International Biotech Limited (YBGJ) has an earnings quality ratio of 0.52x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.